Researchers at the Medical Oncology Unit, University of Siena, Viale Bracci 11, 53100, Siena, Italy performed a randomized phase II study which compared the activity and safety of the combination docetaxel (D)/epirubicin (EPI) with the standard of care D/prednisone (P) in men with advanced castrate-resistant prostate cancer (CRPC). […]
In prior studies with men who have had a PSA recurrence after radiotherapy (RT), intermittent androgen suppression (IAS) has been suggested to improve quality of life (QoL) but effects on survival are unknown. The researchers performed an inter-group randomized phase III trial, which compared IAS vs continuous androgen deprivation (CAD) to test overall survival (OS) [...]
Can IxMP Be Used as a Second or Third-Line Chemotherapy for Metastatic Castrate Resistant Prostate Cancer? There was a report recently released about a Phase 2 study from the Department of Defense funded Prostate Cancer Clinical Trials Consortium that suggests that ixabepilone + mitoxantrone + prednisone may have clinically significant activity as a form of [...]
The latest from Jan Manarite of PCRI about the getting early access to Abiraterone for men with advanced prostate cancer and who have failed chemotherapy: Abiraterone expanded Access Trial Site Contact Info – 2/7/11 (800) 457-6399 M-F, 9am –5pm, EST TRIAL link: http://www.clinicaltrials.gov/ct2/show/NCT01217697?term=abiraterone&recr=Open&rank=6 Basic Criteria: 1. testosterone less than 50 2. metastatic 3. no brain [...]
Malecare is proud to announce that we are now partnering with the Clinical Trials Resource Center. This partnership allows us to offer you, through our web site (www.malecare.org), CenterWatch’s data base of clinical trials that are being conducted both in the United States and internationally. CenterWatch is the leading publisher of information on clinical research [...]